Equities

ReNeuron Group PLC

ReNeuron Group PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)3.38
  • Today's Change0.00 / 0.00%
  • Shares traded177.62k
  • 1 Year change-63.51%
  • Beta1.5845
Data delayed at least 20 minutes, as of Feb 05 2024 14:22 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ReNeuron Group plc is a United Kingdom-based Stem Cell and Exosome Technologies company that utilizes its stem cell technologies to develop treatments for disease with unmet needs. The Company has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. The Company’s CustomEX platform can be optimized for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. The Company offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, the Company has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

  • Revenue in GBP (TTM)249.00k
  • Net income in GBP-5.07m
  • Incorporated2005
  • Employees34.00
  • Location
    ReNeuron Group PLCPencoed Business ParkBRIDGEND CF35 5HYUnited KingdomGBR
  • Phone+44 203 819 8400
  • Fax+44 148 353 4864
  • Websitehttps://www.reneuron.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ovoca Bio PLC0.00-2.00m570.95k5.00--0.1318-----0.0245-0.02450.000.05310.00----0.00-27.00-17.82-32.86-19.39--------4.68-48.640.00-------6.96------
Voyager Life PLC314.00k-1.10m1.35m28.00--2.12--4.29-0.0912-0.09120.02530.0440.18971.583.8511,214.29-66.51---77.02--41.72---350.64--2.83-69.500.4625--59.55---38.70------
Nuformix PLC0.00-436.95k1.56m2.00--0.3371-----0.0006-0.00060.000.00560.00-------9.50---9.95--------------0.00--------------
N4 Pharma PLC0.00-925.31k1.81m5.00--1.09-----0.0042-0.00420.000.00620.00----0.00-59.56-58.71-65.34-63.61-------8,155.51---1,910.050.00------33.35------
ReNeuron Group Plc249.00k-5.07m1.93m34.00--0.7966--7.75-0.0888-0.08880.00440.04240.0246--0.64427,323.53-50.10-43.12-101.09-58.50-----2,037.35-714.73----0.1247--31.5165.2644.18---1.31--
Evgen Pharma PLC838.00k-3.35m2.41m7.00--0.6113--2.87-0.0122-0.01220.00310.01430.1406--1.81119,714.30-56.25-42.37-60.57-46.32-----400.12-2,324.84----0.00-------48.10---32.24--
Hellenic Dynamics PLC-100.00bn-100.00bn3.40m25.00--4.48----------0.006----------------------------0.3029--------------
Fusion Antibodies PLC1.58m-2.84m3.67m50.00--1.57--2.33-0.0861-0.08610.04360.02450.52293.151.8831,580.00-93.94-31.29-130.56-37.72-7.4142.58-179.67-48.252.32--0.0313---39.551.52-116.33---23.83--
IXICO PLC6.67m-1.18m4.18m89.00--0.3659--0.6275-0.0244-0.02440.1380.23640.4822--2.8274,887.64-8.524.35-9.575.3349.0662.09-17.676.61----0.03270.00-22.894.32-214.15--92.12--
Genflow Biosciences PLC0.00-1.18m4.24m0.00--2.47-----0.004-0.0040.000.00590.00-------48.01---51.61-------------6,299.750.00-------35.13------
Oxford Cannabinoid Tchnlgs Hldngs PLC0.00-4.24m4.68m7.00--2.12-----0.0044-0.00440.000.0020.00----0.00-82.98-56.41-104.70-66.13------------0.00-------26.16------
ValiRx Plc0.00-2.41m5.10m8.00--0.937-----0.0256-0.02560.000.04110.00----0.00-69.67-58.85-69.21-68.96-----------575.810.0072-------55.87------
Data as of Feb 05 2024. Currency figures normalised to ReNeuron Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

31.02%Per cent of shares held by top holders
HolderShares% Held
Octopus Investments Ltd.as of 04 Jun 20213.35m5.86%
Hargreaves Lansdown Asset Management Ltd.as of 01 Feb 20243.34m5.85%
Schroder Investment Management Ltd.as of 12 Mar 20212.84m4.96%
KW Investment Management Ltd.as of 01 Feb 20242.79m4.88%
IG Markets Ltd.as of 01 Feb 20242.38m4.16%
HSBC Bank Plc (Market-Maker)as of 01 Feb 2024698.00k1.22%
Toscafund Asset Management LLPas of 31 Dec 2022667.11k1.17%
abrdn Investments Ltd.as of 01 Feb 2024591.00k1.03%
HSBC Global Asset Management (UK) Ltd.as of 01 Feb 2024583.00k1.02%
James Brearley & Sons Ltd.as of 01 Feb 2024501.00k0.88%
More ▼
Data from 30 Sep 2023 - 14 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.